drugset / Trial / NCT00834639

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

NCT00834639

Phase 1 Completed 24 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

This study will compare the relative bioavailability of 500 mg Divalproex Sodium Delayed-Release Tablets with that of 500 mg Depakote® Tablets following a single oral dose (1 x 500 mg tablets)in healthy subjects under fasting conditions.

Timeline

Start
2003-09
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule 500 mg Oral

Indications

No indication recorded.